started · updated
Spanish health agency advises barrier contraception for Mounjaro users
The Spanish Agency for Medicines and Health Products (AEMPS) has updated its contraceptive recommendations for individuals using Mounjaro, a medication containing tirzepatide used to treat type 2 diabetes, obesity, and overweight.
For women using oral contraceptives while on tirzepatide, the agency advises adding a barrier method, such as a condom, during the first four weeks of treatment and for four weeks following any dose increase. Alternatively, patients may switch to a non-oral contraceptive method.
These updates follow reviews by the European Medicines Agency (EMA) committees, specifically the Pharmacovigilance Risk Assessment Committee (PRAC) and the Committee for Medicinal Products for Human Use (CHMP). Both committees concluded that available information regarding the impact of tirzepatide on the efficacy of oral contraceptives is currently limited.
Existing guidelines already state that the drug should not be used during pregnancy or by women of childbearing potential who are not using contraception. Those planning to become pregnant are advised to discontinue treatment at least one month in advance. Following a European Commission decision, manufacturer Lilly will issue an information letter to healthcare professionals, and the warnings will be included in the drug's technical data sheet and patient leaflets.
Entities
European Medicines Agency · Lilly · Mounjaro · Spain · Spanish Agency for Medicines and Health Products